Company Filing History:
Years Active: 2024
Title: Renaldas Augulis: Innovator in Tumor-Stroma Interface Detection
Introduction
Renaldas Augulis is a prominent inventor based in Vilnius, Lithuania. He has made significant contributions to the field of cancer research through his innovative patent. His work focuses on improving the assessment of anti-tumor responses, which is crucial for patient survival.
Latest Patents
Renaldas Augulis holds a patent titled "Automated Tumour-Stroma interface zone detection for anti-tumour response assessment by immunogradient indicators." This patent presents a novel method for automatically sampling the tumor/stroma interface zone from microscopy image analysis data. The method delineates the tumor edge using explicit rules in grid-subsampled tissue areas. It samples the interface zone of controlled width and ranks it by the distance from the edge to compute tumor-infiltrating lymphocyte (TIL) density profiles. The resulting Immunogradient indicators reflect TIL 'gravitation' towards the tumor. This method has been applied to CD8 immunohistochemistry images of surgically excised breast and colorectal cancers, demonstrating strong prognostic value and outperforming existing methods.
Career Highlights
Renaldas Augulis is affiliated with Vilnius University, where he conducts his research and develops his innovative methods. His work has garnered attention for its potential to enhance the precision of immune response measurements in tumor-host interactions. This advancement is vital for predicting disease outcomes and therapy effectiveness.
Collaborations
Renaldas collaborates with notable colleagues, including Arvydas Laurinavicius and Allan Rasmusson. Their combined expertise contributes to the advancement of research in cancer treatment and patient care.
Conclusion
Renaldas Augulis is a key figure in the field of cancer research, with his innovative patent paving the way for improved patient outcomes. His contributions highlight the importance of automated methods in medical research and the potential for significant advancements in cancer treatment.